- Home
- CJET vs IMRN Comparison
CJET vs IMRN Comparison
Compare CJET & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- IMRN
- Stock Information
- Founded
- CJET 2009
- IMRN 1994
- Country
- CJET China
- IMRN Australia
- Employees
- CJET N/A
- IMRN N/A
- Industry
- CJET Auto Manufacturing
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CJET Consumer Discretionary
- IMRN Health Care
- Exchange
- CJET Nasdaq
- IMRN Nasdaq
- Market Cap
- CJET 14.3M
- IMRN 15.0M
- IPO Year
- CJET N/A
- IMRN N/A
- Fundamental
- Price
- CJET $1.76
- IMRN $2.15
- Analyst Decision
- CJET
- IMRN Strong Buy
- Analyst Count
- CJET 0
- IMRN 1
- Target Price
- CJET N/A
- IMRN $5.00
- AVG Volume (30 Days)
- CJET 69.5K
- IMRN 21.6K
- Earning Date
- CJET 01-28-2025
- IMRN 02-26-2025
- Dividend Yield
- CJET N/A
- IMRN N/A
- EPS Growth
- CJET N/A
- IMRN N/A
- EPS
- CJET N/A
- IMRN N/A
- Revenue
- CJET $10,275,000.00
- IMRN $3,271,194.00
- Revenue This Year
- CJET N/A
- IMRN N/A
- Revenue Next Year
- CJET N/A
- IMRN N/A
- P/E Ratio
- CJET N/A
- IMRN N/A
- Revenue Growth
- CJET 31.31
- IMRN 171.67
- 52 Week Low
- CJET $1.65
- IMRN $1.59
- 52 Week High
- CJET $23.94
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- CJET 37.95
- IMRN 56.18
- Support Level
- CJET $1.93
- IMRN $1.85
- Resistance Level
- CJET $2.08
- IMRN $2.20
- Average True Range (ATR)
- CJET 0.17
- IMRN 0.22
- MACD
- CJET -0.06
- IMRN 0.01
- Stochastic Oscillator
- CJET 10.71
- IMRN 57.47
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.